Literature DB >> 22542012

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Amy Lew Tsuhako1, David S Brown, Elena S Koltun, Naing Aay, Arlyn Arcalas, Vicky Chan, Hongwang Du, Stefan Engst, Maurizio Franzini, Adam Galan, Ping Huang, Stuart Johnston, Brian Kane, Moon H Kim, A Douglas Laird, Rui Lin, Lillian Mock, Iris Ngan, Michael Pack, Gordon Stott, Thomas J Stout, Peiwen Yu, Cristiana Zaharia, Wentao Zhang, Peiwen Zhou, John M Nuss, Patrick C Kearney, Wei Xu.   

Abstract

A series of substituted benzofuropyrimidinones with pan-PIM activities and excellent selectivity against a panel of diverse kinases is described. Initial exploration identified aryl benzofuropyrimidinones that were potent, but had cell permeability limitation. Using X-ray crystal structures of the bound PIM-1 complexes with 3, 5m, and 6d, we were able to guide the SAR and identify the alkyl benzofuropyrimidinone (6l) with good PIM potencies, permeability, and oral exposure.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542012     DOI: 10.1016/j.bmcl.2012.04.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.

Authors:  Rand Shahin; Lubna Swellmeen; Omar Shaheen; Nour Aboalhaija; Maha Habash
Journal:  J Comput Aided Mol Des       Date:  2015-12-19       Impact factor: 3.686

2.  The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.

Authors:  Nanda Kumar Sasi; Kanchan Tiwari; Fen-Fen Soon; Dorine Bonte; Tong Wang; Karsten Melcher; H Eric Xu; Michael Weinreich
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

3.  A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Authors:  Jason M Foulks; Kent J Carpenter; Bai Luo; Yong Xu; Anna Senina; Rebecca Nix; Ashley Chan; Adrianne Clifford; Marcus Wilkes; David Vollmer; Benjamin Brenning; Shannon Merx; Shuping Lai; Michael V McCullar; Koc-Kan Ho; Daniel J Albertson; Lee T Call; Jared J Bearss; Sheryl Tripp; Ting Liu; Bret J Stephens; Alexis Mollard; Steven L Warner; David J Bearss; Steven B Kanner
Journal:  Neoplasia       Date:  2014-06-18       Impact factor: 5.715

4.  Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.

Authors:  Jozefina Bogusz; Karol Zrubek; Krzysztof P Rembacz; Przemyslaw Grudnik; Przemyslaw Golik; Malgorzata Romanowska; Benedykt Wladyka; Grzegorz Dubin
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

5.  Synthesis of new pyridothienopyrimidinone and pyridothienotriazolopyrimidine derivatives as pim-1 inhibitors.

Authors:  Hala B El-Nassan; Bassem H Naguib; Engy A Beshay
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

6.  Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.

Authors:  Bassem H Naguib; Hala B El-Nassan; Tamer M Abdelghany
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  5-Bromo-2-hy-droxy-benzonitrile.

Authors:  Scott Oh; Joseph M Tanski
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.